PortalPublikationenDose prescription for stereotactic body radiotherapy

Dose prescription for stereotactic body radiotherapy

Standard

Dose prescription for stereotactic body radiotherapy : general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. / Brunner, Thomas B; Boda-Heggemann, Judit; Bürgy, Daniel; Corradini, Stefanie; Dieckmann, Ute Karin; Gawish, Ahmed; Gerum, Sabine; Gkika, Eleni; Grohmann, Maximilian; Hörner-Rieber, Juliane; Kirste, Simon; Klement, Rainer J; Moustakis, Christos; Nestle, Ursula; Niyazi, Maximilian; Rühle, Alexander; Lang, Stephanie-Tanadini; Winkler, Peter; Zurl, Brigitte; Wittig-Sauerwein, Andrea; Blanck, Oliver.

in: STRAHLENTHER ONKOL, Jahrgang 200, Nr. 9, 09.2024, S. 737-750.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Brunner, TB, Boda-Heggemann, J, Bürgy, D, Corradini, S, Dieckmann, UK, Gawish, A, Gerum, S, Gkika, E, Grohmann, M, Hörner-Rieber, J, Kirste, S, Klement, RJ, Moustakis, C, Nestle, U, Niyazi, M, Rühle, A, Lang, S-T, Winkler, P, Zurl, B, Wittig-Sauerwein, A & Blanck, O 2024, 'Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery', STRAHLENTHER ONKOL, Jg. 200, Nr. 9, S. 737-750. https://doi.org/10.1007/s00066-024-02254-2

APA

Brunner, T. B., Boda-Heggemann, J., Bürgy, D., Corradini, S., Dieckmann, U. K., Gawish, A., Gerum, S., Gkika, E., Grohmann, M., Hörner-Rieber, J., Kirste, S., Klement, R. J., Moustakis, C., Nestle, U., Niyazi, M., Rühle, A., Lang, S-T., Winkler, P., Zurl, B., ... Blanck, O. (2024). Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. STRAHLENTHER ONKOL, 200(9), 737-750. https://doi.org/10.1007/s00066-024-02254-2

Vancouver

Brunner TB, Boda-Heggemann J, Bürgy D, Corradini S, Dieckmann UK, Gawish A et al. Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. STRAHLENTHER ONKOL. 2024 Sep;200(9):737-750. https://doi.org/10.1007/s00066-024-02254-2

Bibtex

@article{df1e01e8c6d349f28f6641fd0b8f7e37,
title = "Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery",
abstract = "PURPOSE AND OBJECTIVE: To develop expert consensus statements on multiparametric dose prescriptions for stereotactic body radiotherapy (SBRT) aligning with ICRU report 91. These statements serve as a foundational step towards harmonizing current SBRT practices and refining dose prescription and documentation requirements for clinical trial designs.MATERIALS AND METHODS: Based on the results of a literature review by the working group, a two-tier Delphi consensus process was conducted among 24 physicians and physics experts from three European countries. The degree of consensus was predefined for overarching (OA) and organ-specific (OS) statements (≥ 80%, 60-79%, < 60% for high, intermediate, and poor consensus, respectively). Post-first round statements were refined in a live discussion for the second round of the Delphi process.RESULTS: Experts consented on a total of 14 OA and 17 OS statements regarding SBRT of primary and secondary lung, liver, pancreatic, adrenal, and kidney tumors regarding dose prescription, target coverage, and organ at risk dose limitations. Degree of consent was ≥ 80% in 79% and 41% of OA and OS statements, respectively, with higher consensus for lung compared to the upper abdomen. In round 2, the degree of consent was ≥ 80 to 100% for OA and 88% in OS statements. No consensus was reached for dose escalation to liver metastases after chemotherapy (47%) or single-fraction SBRT for kidney primaries (13%). In round 2, no statement had 60-79% consensus.CONCLUSION: In 29 of 31 statements a high consensus was achieved after a two-tier Delphi process and one statement (kidney) was clearly refused. The Delphi process was able to achieve a high degree of consensus for SBRT dose prescription. In summary, clear recommendations for both OA and OS could be defined. This contributes significantly to harmonization of SBRT practice and facilitates dose prescription and reporting in clinical trials investigating SBRT.",
author = "Brunner, {Thomas B} and Judit Boda-Heggemann and Daniel B{\"u}rgy and Stefanie Corradini and Dieckmann, {Ute Karin} and Ahmed Gawish and Sabine Gerum and Eleni Gkika and Maximilian Grohmann and Juliane H{\"o}rner-Rieber and Simon Kirste and Klement, {Rainer J} and Christos Moustakis and Ursula Nestle and Maximilian Niyazi and Alexander R{\"u}hle and Stephanie-Tanadini Lang and Peter Winkler and Brigitte Zurl and Andrea Wittig-Sauerwein and Oliver Blanck",
note = "{\textcopyright} 2024. The Author(s).",
year = "2024",
month = sep,
doi = "10.1007/s00066-024-02254-2",
language = "English",
volume = "200",
pages = "737--750",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "9",

}

RIS

TY - JOUR

T1 - Dose prescription for stereotactic body radiotherapy

T2 - general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery

AU - Brunner, Thomas B

AU - Boda-Heggemann, Judit

AU - Bürgy, Daniel

AU - Corradini, Stefanie

AU - Dieckmann, Ute Karin

AU - Gawish, Ahmed

AU - Gerum, Sabine

AU - Gkika, Eleni

AU - Grohmann, Maximilian

AU - Hörner-Rieber, Juliane

AU - Kirste, Simon

AU - Klement, Rainer J

AU - Moustakis, Christos

AU - Nestle, Ursula

AU - Niyazi, Maximilian

AU - Rühle, Alexander

AU - Lang, Stephanie-Tanadini

AU - Winkler, Peter

AU - Zurl, Brigitte

AU - Wittig-Sauerwein, Andrea

AU - Blanck, Oliver

N1 - © 2024. The Author(s).

PY - 2024/9

Y1 - 2024/9

N2 - PURPOSE AND OBJECTIVE: To develop expert consensus statements on multiparametric dose prescriptions for stereotactic body radiotherapy (SBRT) aligning with ICRU report 91. These statements serve as a foundational step towards harmonizing current SBRT practices and refining dose prescription and documentation requirements for clinical trial designs.MATERIALS AND METHODS: Based on the results of a literature review by the working group, a two-tier Delphi consensus process was conducted among 24 physicians and physics experts from three European countries. The degree of consensus was predefined for overarching (OA) and organ-specific (OS) statements (≥ 80%, 60-79%, < 60% for high, intermediate, and poor consensus, respectively). Post-first round statements were refined in a live discussion for the second round of the Delphi process.RESULTS: Experts consented on a total of 14 OA and 17 OS statements regarding SBRT of primary and secondary lung, liver, pancreatic, adrenal, and kidney tumors regarding dose prescription, target coverage, and organ at risk dose limitations. Degree of consent was ≥ 80% in 79% and 41% of OA and OS statements, respectively, with higher consensus for lung compared to the upper abdomen. In round 2, the degree of consent was ≥ 80 to 100% for OA and 88% in OS statements. No consensus was reached for dose escalation to liver metastases after chemotherapy (47%) or single-fraction SBRT for kidney primaries (13%). In round 2, no statement had 60-79% consensus.CONCLUSION: In 29 of 31 statements a high consensus was achieved after a two-tier Delphi process and one statement (kidney) was clearly refused. The Delphi process was able to achieve a high degree of consensus for SBRT dose prescription. In summary, clear recommendations for both OA and OS could be defined. This contributes significantly to harmonization of SBRT practice and facilitates dose prescription and reporting in clinical trials investigating SBRT.

AB - PURPOSE AND OBJECTIVE: To develop expert consensus statements on multiparametric dose prescriptions for stereotactic body radiotherapy (SBRT) aligning with ICRU report 91. These statements serve as a foundational step towards harmonizing current SBRT practices and refining dose prescription and documentation requirements for clinical trial designs.MATERIALS AND METHODS: Based on the results of a literature review by the working group, a two-tier Delphi consensus process was conducted among 24 physicians and physics experts from three European countries. The degree of consensus was predefined for overarching (OA) and organ-specific (OS) statements (≥ 80%, 60-79%, < 60% for high, intermediate, and poor consensus, respectively). Post-first round statements were refined in a live discussion for the second round of the Delphi process.RESULTS: Experts consented on a total of 14 OA and 17 OS statements regarding SBRT of primary and secondary lung, liver, pancreatic, adrenal, and kidney tumors regarding dose prescription, target coverage, and organ at risk dose limitations. Degree of consent was ≥ 80% in 79% and 41% of OA and OS statements, respectively, with higher consensus for lung compared to the upper abdomen. In round 2, the degree of consent was ≥ 80 to 100% for OA and 88% in OS statements. No consensus was reached for dose escalation to liver metastases after chemotherapy (47%) or single-fraction SBRT for kidney primaries (13%). In round 2, no statement had 60-79% consensus.CONCLUSION: In 29 of 31 statements a high consensus was achieved after a two-tier Delphi process and one statement (kidney) was clearly refused. The Delphi process was able to achieve a high degree of consensus for SBRT dose prescription. In summary, clear recommendations for both OA and OS could be defined. This contributes significantly to harmonization of SBRT practice and facilitates dose prescription and reporting in clinical trials investigating SBRT.

U2 - 10.1007/s00066-024-02254-2

DO - 10.1007/s00066-024-02254-2

M3 - SCORING: Review article

C2 - 38997440

VL - 200

SP - 737

EP - 750

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 9

ER -